Machine signal
Active cluster sell — 9 distinct insiders, $67M, window ends Sep 17, 2026.
Figures computed from official regulatory filings — .
Analysttarget 75.21 USD (+30%) · consensus 4.73/5 · 14 buy · 1 hold · 0 sell
Ownershipinsiders 0.69% · institutions 115.07% · short 17.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Travere Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
54 buys454 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Heerma Peter | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ROTE WILLIAM E. | Sell | $4.1M | Unusual size | SEC |
| Dube Eric M | Sell | $3.9M | Unusual size | SEC |
| Cline Christopher R. | Sell | $26.1K | SEC |
| Inrig Jula | Sell | $101.9K | SEC |
| Heerma Peter | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Inrig Jula | Sell | $1.1M | Unusual size | SEC |
| Inrig Jula | Sell | $1.6M | Unusual size | SEC |
| REED ELIZABETH E | Sell | $19.6K | SEC |
| Calvin Sandra | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Heerma Peter | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Inrig Jula | Exercise | $289.3K | SEC |
| Dube Eric M | Sell | $1.8M | SEC |
| ROTE WILLIAM E. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ROTE WILLIAM E. | Exercise | $712.1K | SEC |
| Heerma Peter | Exercise | $476.2K | SEC |
| Heerma Peter | Sell | $4.5M | Unusual size | SEC |
| Heerma Peter | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ROTE WILLIAM E. | Sell | $4M | Unusual size | SEC |
| ROTE WILLIAM E. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Heerma Peter | Exercise | $30.9K | SEC |
| Cline Christopher R. | Sell | $1.3M | Unusual size | SEC |
| Heerma Peter | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ROTE WILLIAM E. | Exercise | $850.3K | SEC |
| Dube Eric M | Exercise | $2.5M | SEC |